Viking Touts Promising Phase I Weight Loss Data for Obesity Pill Candidate
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy VK2735 exceeded expectations, with “class-leading” weight loss. Patients on 100-miligram doses of the pill lost 8.
Wall Street Lunch: Viking Weight-Loss Pill Data Is Striking
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 study by end of 2024. Market cautious ahead of election and Fed decision. Bank of America upgrades Peloton to Buy, citing potential for ...
What are top fat burners? Do they work? Why should I select a fat burner, especially for women? Which fat burner is better, ...
Viking Therapeutics Inc.’s stock rose 2% Friday as excitement continued to build about data on its oral weight-loss drug the ...
Losing more than 8% of weight in less than a month. This is the promise of a pill under experimentation in the laboratories ...
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, ...
People taking phentermine can lose over 7% of their body weight, or at least 8 pounds.
Discover the best and safest weight loss supplements that support your healthy dieting and exercise routine. From fat burners ...
Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...
Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...
AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback